Abstract
We thank Roush et al for their letter.1 We believe both their2 and our analyses3 provide some support for recent suggestions that chlorthalidone may be superior to hydrochlorothiazide (HCT) for prevention of cardiovascular events at doses typically used in the clinical setting.4,5 The data that they show relating relative risk of cardiovascular events to reduction in office systolic …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
